Search results
Found 24 matches for
TCRs drive CARs
1 May 2025
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues—addressing a major challenge in current immunotherapy.
Cellular roadmap reveals new paths to treating inflammatory bowel disease
22 October 2024
In a world first, researchers at the Kennedy Institute, Oxford have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases. They have discovered why some patients benefit from this therapy while others do not, potentially paving the way for new therapies.
New study reveals how T cells gain and maintain tolerance to gut bacteria
4 April 2024
The immune system in the intestine maintains a careful balance, tolerating our long-term resident (commensal) gut bacteria while defending against invading pathogens. Under certain circumstances, dysregulation of our intestinal immune response to commensal and pathogenic microbes can drive inflammatory disease.
New research endoscopy service launches today
2 October 2023
The launch of a new endoscopy service at the Oxford Experimental Medicine Clinical Research Facility (EMCRF) will enhance the collection of data for research projects at NDORMS and across the University of Oxford.
New partnership will accelerate AI-driven immunotherapies
17 May 2023
Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies
Leducq Foundation grant boosts cardiovascular research
11 October 2022
The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.
MRC funding awarded to Kennedy researchers
8 September 2022
Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.
Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself
11 January 2022
A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.
Large-scale genetic study reveals new clues for the shared origins of irritable bowel syndrome and mental health disorders
5 November 2021
An international study of more than 50,000 people with irritable bowel syndrome (IBS) has revealed that IBS symptoms may be caused by the same biological processes as conditions such as anxiety. The research highlights the close relationship between brain and gut health and paves the way for development of new treatments.
Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells
26 July 2021
Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.
Repurposed drug can induce remission of inflammatory arthritis
20 May 2021
Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.
Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease
18 December 2020
Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.
Dissecting TNF signalling in inflammatory disease
28 October 2019
New research from Dr Richard Williams’ group at the Kennedy Institute suggests a route for the development of more selective – and effective – therapies for immune-mediated inflammatory disease.
Protective mediators can help heal injured tendon cells by attacking inflammation
11 October 2019
Findings reported in The American Journal of Pathology suggest specialized proresolving mediators may become therapeutics that alleviate chronic tendon inflammation
One step closer to targeted therapies for joint inflammation
4 January 2019
New discoveries on how tissue cells, known as stromal cells contribute to chronic joint inflammation could hold the key to innovative targeted treatments for patients with refractory joint disease.
Botnar researchers lead in identifying new inflammatory target in Spondyloarthritis patients
23 November 2017
Spondyloarthritis encompasses a group of common inflammatory diseases caused by an overactive immune response affecting up to half a million people in the UK alone.
ImPAcT of inflammation in Achilles tendinopathy
9 November 2017
In a new study published in the British Journal of Sports Medicine, scientists at NDORMS investigated if chronic inflammation was a feature of Achilles tendinopathy and rupture.
Targeting tendinopathy resolution
8 September 2017
In a new study published in journal Scientific Reports, scientists at NDORMS and Queen Mary University of London have identified reasons underpinning the failure of inflammation to resolve in disorders of musculoskeletal soft tissues such as tendons.